Atossa Therapeutics is shifting its (Z)-endoxifen clinical focus to newly diagnosed breast cancer patients before surgery, moving earlier than the metastatic se

Atossa Therapeutics is shifting its (Z)-endoxifen clinical focus to newly diagnosed breast cancer patients before surgery, moving earlier than the metastatic settings often used in drug development. The strategy could sharpen biologic insight and expand oncology applications.